MustangBio
    • About
      • About Mustang Bio
      • Leadership
      • Board of Directors
      • In the News
      • Contact
    • Our Approach
      • Our Approach
      • About Gene Therapy
      • About CAR T Cell Therapy
      • Publications
      • Manufacturing
    • Pipeline
      • Pipeline
      • Clinical Trials
    • Partnering
      • Partnering
      • Active Collaborations
    • Careers
    • Investor Relations
      • News & Events
      • Company Info
      • Financial Info
      • Stock Data
      • SEC Filings
      • Governance

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
    • News & Events

    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
    November 14, 2017

    Mustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights

    November 14, 2017

    Mustang Bio Announces Appointment of Brian Achenbach as Vice President of Finance and Corporate Controller

    November 1, 2017

    Mustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting

    October 31, 2017

    Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain

    October 30, 2017

    Mustang Bio Establishes CAR T Cell Therapy Manufacturing Facility in Massachusetts

    October 11, 2017

    Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma

    September 14, 2017

    Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies

    September 5, 2017

    Mustang Bio to Present at the CAR-TCR Summit 2017

    August 22, 2017

    Mustang Bio Commences Trading on the NASDAQ Global Market

    • arrow_back
    • 1
    • …
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    rss_feed News RSS
    • Email Alerts
    • Contacts
    • RSS News Feed

    377 Plantation Street • Worcester, MA 01605

    781-652-4500 info@mustangbio.com

    Twitter Linkedin

    © Copyright 2023 Mustang Bio